HPV E6 proteins target Ubc9, the SUMO conjugating enzyme

Virus Research

Volumn 158, Issue 1-2, 2011, Pages 199-208

  Heaton, Phillip R ^a   Deyrieux, Adeline F ^a,b   Bian, Xue Lin ^a,c   Wilson, Van G ^a  

^a TEXAS A M COLLEGE OF MEDICINE   (United States)

^b Texas A and M University ^*  (United States)

^c TEXAS A AND M UNIVERSITY   (United States)

Author keywords

E6; HaCaT; Human papillomavirus; Proteomics; SUMO; Ubc9

Indexed keywords

ALPHA TUBULIN; ENHANCED GREEN FLUORESCENT PROTEIN; PROTEASOME; PROTEIN E6; PROTEIN P53; PROTEIN UBC9; SUMO 1 PROTEIN; SUMO 3 PROTEIN; SUMO PROTEIN; TUBULIN; UBIQUITIN;

ARTICLE; CELL DIFFERENTIATION; CONTROLLED STUDY; GENETIC TRANSCRIPTION; HOST CELL; HUMAN; IN VITRO STUDY; KERATINOCYTE; NONHUMAN; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN EXPRESSION; PROTEIN PROCESSING; PROTEIN PROTEIN INTERACTION; PROTEIN STABILITY; SUMOYLATION; VIRUS REPLICATION; WART VIRUS;

CELL LINE; HUMANS; KERATINOCYTES; ONCOGENE PROTEINS, VIRAL; PAPILLOMAVIRIDAE; PROTEIN BINDING; PROTEIN INTERACTION MAPPING; REPRESSOR PROTEINS; TRANSCRIPTION, GENETIC; UBIQUITIN-CONJUGATING ENZYMES; VIRULENCE FACTORS;

HUMAN PAPILLOMAVIRUS;

EID: 79956318963     PISSN: 01681702     EISSN: 18727492     Source Type: Journal    
DOI: 10.1016/j.virusres.2011.04.001     Document Type: Article

References (57)

1. Adamson A.L. Effects of SUMO-1 upon Epstein-Barr virus BZLF1 function and BMRF1 expression. Biochem. Biophys. Res. Commun. 2005, 336(1):22-28.
2. Adamson A.L., Kenney S. Epstein-Barr virus immediate-early protein BZLF1 is SUMO-1 modified and disrupts promyelocytic leukemia bodies. J. Virol. 2001, 75(5):2388-2399.
3. Bailey D., O'Hare P. Herpes simplex virus 1 ICPO co-localizes with a SUMO-specific protease. J. Gen. Virol. 2002, 83:2951-2964.
4. Bernat A., Avvakumov N., Mymryk J.S., Banks L. Interaction between the HPV E7 oneoprotein and the transcriptional coactivator p300. Oncogene 2003, 22(39):5927-5937.
5. Bischof O., Schwamborn K., Martin N., Werner A., Sustmann C., Grosschedl R., Dejean A. The E3 SUMO ligase PIASy is a regulator of cellular senescence and apoptosis. Mol. Cell 2006, 22(6):783-794.
6. Boggio R., Chiocca S. Gam1 and the SUMO pathway. Cell Cycle 2005, 4(4):533-535.
7. Boggio R., Chiocca S. Viruses and sumoylation: recent highlights. Curr. Opin. Microbiol. 2006, 9(4):430-436.
8. Boggio R., Colombo R., Hay R.T., Draetta G.F., Chiocca S. A mechanism for inhibiting the SUMO pathway. Mol. Cell 2004, 16(4):549-561.
9. Boggio R., Passafaro A., Chiocca S. Targeting SUMO E1 to ubiquitin ligases - a viral strategy to counteract sumoylation. J. Biol. Chem. 2007, 282(21):15376-15382.
10. Camus S., Menendez S., Cheok C.F., Stevenson L.F., Lain S., Lane D.P. Ubiquitin-independent degradation of p53 mediated by high-risk human papillomavirus protein E6. Oncogene 2007, 26(28):4059-4070.
11. Chang P.C., Izumiya Y., Wu C.Y., Fitzgerald L.D., Campbell M., Ellison T.J., Lam K.S., Luciw P.A., Kung H.J. Kaposi's sarcoma-associated herpesvirus (KSHV) encodes a SUMO E3 ligase that is SIM-dependent and SUMO-2/3-specific. J. Biol. Chem. 2010, 285(8):5266-5273.
12. Chang T.H., Kubota T., Matsuoka M., Jones S., Bradfute S.B., Bray M., Ozato K. Ebola zaire virus blocks type I interferon production by exploiting the host SUMO modification machinery. PLoS Pathogens 2009, 5(6):493-1493.
13. Cho Y.S., Kang J.W., Cho M., Cho C.W., Lee S., Choe Y.K., Kim Y., Choi I., Park S.N., Kim S., Dinarello C.A., Yoon D.Y. Down modulation of IL-18 expression by human papillomavirus type 16 E6 oncogene via binding to IL-18. FEBS Lett. 2001, 501(2-3):139-145.
14. Desaintes C., Demeret C., Goyat S., Yaniv M., Thierry F. Expression of the papillomavirus E2 protein in HeLa cells leads to apoptosis. EMBO J. 1997, 16(3):504-514.
15. Desaintes C., Goyat S., Garbay S., Yaniv M., Thierry F. Papillomavirus E2 induces p53-independent apoptosis in HeLa cells. Oncogene 1999, 18(32):4538-4545.
16. Deyrieux A., Wilson V.G. Viral interplay with the host sumoylation system. SUMO Regulation of Cellular Processes 2009, 315-329. Springer, New York. V.G. Wilson (Ed.).
17. Deyrieux A.F., Rosas-Acosta G., Ozbun M.A., Wilson V.G. Sumoylation dynamics during keratinocyte differentiation. J. Cell Sci. 2007, 120(1):125-136.
18. DiMaio D., Liao J.B. Human papillomaviruses and cervical cancer. Adv. Virus Res. 2006, Vol. 66:125-159.
19. Doorbar J. Molecular biology of human papillomavirus infection and cervical cancer. Clin. Sci. 2006, 110(5):525-541.
20. Filippova M., Johnson M.M., Bautista M., Filippov V., Fodor N., Tungteakkhun S.S., Williams K., Duerksen-Hughes P.J. The large and small isoforms of human papillomavirus type 16 E6 bind to and differentially affect procaspase 8 stability and activity. J. Virol. 2007, 81(8):4116-4129.
21. Gao Q.S., Singh L., Kumar A., Srinivasan S., Wazer D.E., Band V. Human papillomavirus type 16 E6-induced degradation of E6TP1 correlates with its ability to immortalize human mammary epithelial cells. J. Virol. 2001, 75(9):4459-4466.
22. Geiss-Friedlander R., Melchior F. Concepts in sumoylation: a decade on. Nat. Rev. Mol. Cell Biol. 2007, 8(12):947-956.
23. Ghioni P., D'Alessandra Y., Mansueto G., Jaffray E., Hay R.T., La Mantia G., Guerrini L. The protein stability and transcriptional activity of p63 alpha are regulated by SUMO-1 conjugation. Cell Cycle 2005, 4(1):183-190.
24. Ghittoni R., Accardi R., Hasan U., Gheit T., Sylla B., Tommasino M. The biological properties of E6 and E7 oncoproteins from human papillomaviruses. Virus Genes 2010, 40(1):1-13.
25. Gill G. Something about SUMO inhibits transcription. Curr. Opin. Gen. Dev. 2005, 15(5):536-541.
26. Gravel A., Dion V., Cloutier N., Gosselin J., Flamand L. Characterization of human herpesvirus 6 variant B immediate-early 1 protein modifications by small ubiquitin-related modifiers. J. Gen. Virol. 2004, 85:1319-1328.
27. Halbert C.L., Demers G.W., Galloway D.A. The E7 gene of human papillomavirus type 16 is sufficient for immortalization of human epithelial cells. J. Virol. 1991, 65(1):473-478.
28. Hay R.T. SUMO: a history of modification. Mol. Cell 2005, 18(1):1-12.
29. Hebner C.M., Laimins L.A. Human papillomaviruses: basic mechanisms of pathogenesis and oncogenicity. Rev. Med. Virol. 2006, 16(2):83-97.
30. Hofmann H., Floss S., Stamminger T. Covalent modification of the transactivator protein IE2-p86 of human cytomegalovirus by conjugation to the ubiquitin-homologous proteins SUMO-1 and hSMT3b. J. Virol. 2000, 74(6):2510-2524.
31. Jing M., Bohl J., Brimer N., Kinter M., Vande Pol S.B. Degradation of tyrosine phosphatase PTPN3 (PTPH1) by association with oncogenic human papillomavirus E6 proteins. J. Virol. 2007, 81(5):2231-2239.
32. Kerscher O., Felberbaum R., Hochstrasser M. Modification of proteins by ubiquitin and ubiquitin-like proteins. Ann. Rev. Cell Dev. Biol. 2006, 22:159-180.
33. Kroetz M.B. SUMO: a ubiquitin-like protein modifier. Yale J. Biol. Med. 2005, 78(4):197-201.
34. Kuballa P., Matentzoglu K., Scheffner M. The role of the ubiquitin ligase E6-AP in human papillomavirus E6-mediated degradation of PDZ domain-containing proteins. J. Biol. Chem. 2007, 282(1):65-71.
35. Ledl A., Schmidt D., Muller S. Viral oncoproteins E1A and E7 and cellular LxCxE proteins repress SUMO modification of the retinoblastoma tumor suppressor. Oncogene 2005, 24(23):3810-3818.
36. Lethbridge K.J., Scott G.E., Leppard K.N. Nuclear matrix localization and SUMO-1 modification of adenovirus type 5 E1b 55K protein are controlled by E4 Orf6 protein. J. Gen. Virol. 2003, 84:259-268.
37. Magal S.S., Jackman A., Ish-Shalom S., Botzer L.E., Gonen P., Schlegel R., Sherman L. Downregulation of Bax mRNA expression and protein stability by the E6 protein of human papillomavirus 16. J. Gen. Virol. 2005, 86:611-621.
38. Magal S.S., Jackman A., Pei X.F., Schlegel R., Sherman L. Induction of apoptosis in human keratinocytes containing mutated p53 alleles and its inhibition by both the E6 and E7 oncoproteins. Int. J. Cancer 1998, 75(1):96-104.
39. Matsumoto Y., Nakagawa S., Yano T., Takizawa S., Nagasaka K., Nakagawa K., Minaguchi T., Wada O., Ooshi H., Matsumoto K., Yasugi T., Kanda T., Huibregtse J.M., Taketani Y. Involvement of a cellular ubiquitin-protein ligase E6AP in the ubiquitin-mediated degradation of extensive substrates of high-risk human papillomavirus E6. J. Med. Virol. 2006, 78(4):501-507.
40. McMurray H.R., Nguyen D., Westbrook T.F., McCance D.J. Biology of human papillomaviruses [review]. Int. J. Exp. Pathol. 2001, 82(1):15-33.
41. Merkley M.A., Hildebrandt E., Podolsky R.H., Arnouk H., Ferris D.G., Dynan W.S., Stoppler H. Large-scale analysis of protein expression changes in human keratinocytes immortalized by human papilloma virus type 16 E6 and E7 oncogenes. Proteome Sci. 2009, 7:29.
42. Muller S., Dejean A. Viral immediate-early proteins abrogate the modification by SUMO-1 of PML and Sp100 proteins, correlating with nuclear body disruption. J. Virol. 1999, 73(6):5137-5143.
43. Munger K., Howley P.M. Human papillomavirus immortalization and transformation functions. Virus Res. 2002, 89:213-228.
44. Rangasamy D., Wilson V.G. Bovine papillomavirus E1 protein is sumoylated by the host cell Ubc9 protein. J. Biol. Chem. 2000, 275(39):30487-30495.
45. Richard C., Lanner C., Naryzhny S.N., Sherman L., Lee H., Lambert P.F., Zehbe I. The immortalizing and transforming ability of two common human papillomavirus 16 E6 variants with different prevalences in cervical cancer. Oncogene 2010, 29(23):3435-3445.
46. Ro H.S., Koh B.H., Jung S.O., Park H.K., Shin Y.B., Kim M.G., Chung B.H. Surface plasmon resonance imaging protein arrays for analysis of triple protein interactions of HPV, E6 E6AP and p53. Proteomics 2006, 6(7):2108-2111.
47. Rosas-Acosta G., Langereis M.A., Deyrieux A., Wilson V.G. Proteins of the PIAS family enhance the sumoylation of the papillomavirus E1 protein. Virology 2005, 331(1):190-203.
48. Rosas-Acosta G., Russell W.K., Deyrieux A., Russell D.H., Wilson V.G. A universal strategy for proteomic studies of SUMO and other ubiquitin-like modifiers. Mol. Cell. Proteomics 2005, 4(1):56-72.
49. Tao M.F., Kruhlak M., Xia S.H., Androphy E., Zheng Z.M. Signals that dictate nuclear localization of human papillomavirus type 16 oncoprotein E6 in living cells. J. Virol. 2003, 77(24):13232-13247.
50. Thomas M., Glaunsinger B., Pim D., Javier R., Banks L. HPV E6 and MAGUK protein interactions: determination of the molecular basis for specific protein recognition and degradation. Oncogene 2001, 20(39):5431-5439.
51. Vaeteewoottacharn K., Chamutpong S., Ponglikitmongkol M., Angeletti P.C. Differential localization of HPV16 E6 splice products with E6-associated protein. Virol. J. 2005, 2:50.
52. Vertegaal A.C.O., Andersen J.S., Ogg S.C., Hay R.T., Mann M., Lamond A.I. Distinct and overlapping sets of SUMO-1 and SUMO-2 target proteins revealed by quantitative proteomics. Mol. Cell. Proteomics 2006, 5(12):2298-2310.
53. Weaver B.A. Epidemiology and natural history of genital human papillomavirus infection. J. Am. Osteopath. Assoc. 2006, 106(Suppl. 3):S2-S8. 1.
54. Wei Q.Z. Pitx2a binds to human papillomavirus type 18 E6 protein and inhibits E6-mediated p53 degradation in HeLa cells. J. Biol. Chem. 2005, 280(45):37790-37797.
55. Wilkinson K.A., Henley J.M. Mechanisms, regulation and consequences of protein SUMOylation. Biochem. J. 2010, 428:133-145.
56. Wu Y.C., Bian X.L., Heaton P.H., Deyrieux A.F., Wilson V.G. Host cell sumoylation level influences papillomavirus E2 protein stability. Virology 2009, 387(1):176-183.
57. Wu Y.C., Roark A.A., Bian X.L., Wilson V.G. Modification of papillomavirus E2 proteins by the small ubiquitin-like modifier family members (SUMOs). Virology 2008, 378(2):329-338.